Milestone Pharmaceuticals Q3 EPS $(0.18) Beats $(0.21) Estimate, Sales $2.963M Beat $1.143M Estimate
Benzinga Newsdesk 2 hours ago
NewsEarningsEarnings Beats
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 50 percent decrease over losses of $(0.12) per
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 50 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $2.963 million which beat the analyst consensus estimate of $1.143 million by 159.26 percent.